Clinical characteristics influencing the effectiveness of metformin on Japanese type 2 diabetes receiving sulfonylureas

Endocrine Journal

Volumn 54, Issue 2, 2007, Pages 247-253

  Tomioka, Setsuko ^a   Ogata, Hiroyasu ^a   Tamura, Yoshifumi ^b   Shimizu, Tomoaki ^b   Watada, Hirotaka ^b   Fujitani, Yoshio ^b   Kawamori, Ryuzo ^b   Hirose, Takahisa ^b  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glycohemoglobin; Hypertension; Metformin; Sulfonylurea; Systolic blood pressure

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIASTOLE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; SYSTOLE; TREATMENT OUTCOME;

EID: 34249096552     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-162     Document Type: Article

References (29)

1. Reaven GM (1998) Banting lecture 1998: role of insulin resistance in human disease. Diabetes 37: 1595-1607.
2. DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333: 541-549.
3. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865.
4. Ohmura C, Tanaka Y, Mitsuhashi N, Atsumi Y, Matsuoka K, Onuma T, Kawamori R (1998) Efficacy of low-dose metformin in Japanese patients with type 2 diabetes mellitus. CurrTherap Res 59: 889-895.
5. Nagasaka S, Aiso Y, Yosizawa K, Ishibasi S (2004) Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabetic Med 21: 136-141.
6. Reaven GM, Johnston P, Hollenbeck CB, Skowronski R, Zhang JC, Goldfine ID, Chen YD (1992) Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 74: 1020-1026.
7. Taniguchi A, Nakai Y, Tokuyama K (1997) Role of glucose effectiveness in the evolution of NIDDM. In: Bergman RN, Lovejoy JC (eds) The Minimal Model Approach and Determinants of Glucose Tolerance. Louisiana State University Press, Baton Rouge, La: 357-367.
8. Igarashi Y, Mita T, Mizuno R, Watada H, Tanaka Y, Kawamori R, Hirose T (2005) Characteristics of Japanese subjects who progress from normal to impaired glucose tolerance. Longitudinal study excluding changes in body weight. Endocr J 52: 683-689.
9. 3- adrenergic receptor gene is a associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun 215: 555-560.
10. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T (2000) The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271: 212-216.
11. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Tomita M, Kimura S, Ito C, Froguel P, Kadowaki T (2002) Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51: 536-540.
12. Diagnostic criteria of metabolic syndrome (2005) J Jpn Soc Intern Med 94: 188-203.
13. Landin K, Tengborn L, Smith U (1991) Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 229: 181-187.
14. Fanghanel G, Sanchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J (1996) Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care 19: 1185-1189.
15. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.
16. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL (1997) Efficacy of metformin in type 2 diabetes. Results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103: 491-497.
17. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB (1994) Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43: 920-928.
18. Paolisso G, Amato L, Eccellente R, Gambardella A, Tagliamonte MR, Varricchio G, Carella C, Giugliano D, D'Onofrio F (1998) Effect of metformin on food intake in obese subject. Eur J Clin Invest 28: 441-446.
19. Davidson MB, Peters AL (1997) An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 102: 99-110.
20. Cubeddu LX, Bonisch H, Gothert M, Molderrings G, Racke K, Ramadori G, Miller KJ, Schworer H (2000) Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors. Naunyn Schmiedebergs Arch Pharmacol 361: 85-91.
21. Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403.
22. DeFronzo RA, Barzilai N, Simonson DC (1991) Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 73: 1294-1301.
23. Hulman S, Falkner B, Freyvogel N (1993) Insulin resistance in the conscious spontaneously hypertensive rat: euglycemic hyperinsulinemic clamp study. Metabolism 42: 14-18.
24. Leighton B, Sanderson AL, Young ME, Radda GK, Boehm EA, Clark JF (1996) Effects of treatment of spontaneously hypertensive rats with the angiotensin-converting enzyme inhibitor trandolapril and the calcium antagonist verapamil on the sensitivity of glucose metabolism to insulin in rat soleus muscle in vitro. Diabetes 45: S120-124.
25. Katayama S, Inaba M, Maruno Y, Morita T, Awata T, Oka Y (1997) Glucose intolerance in spontaneously hypertensive and Wistar-Kyoto rats: enhanced gene expression and synthesis of skeletal muscle glucose transporter 4. Hypertens Res 20: 279-286.
26. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338: 867-872.
27. Herings RMC, de Boer A, Stricker BH, Leufkens HG, Porsius A (1995) Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 345: 1195-1198.
28. Harano Y, Kageyama A, Hirose J, Asakura Y, Yokota T, Ikebuchi M, Suzuki M, Omae T (1995) Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism 44: 315-319.
29. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P (1999) A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 12: 298-303.